NCT07025564View on ClinicalTrials.gov

MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 28, 2026

Primary Completion Date

April 8, 2027

Study Completion Date

April 8, 2027

Conditions
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Interventions
PROCEDURE

Biospecimen Collection

Undergo bone marrow and blood sample collection

PROCEDURE

Echocardiography Test

Undergo ECHO

DRUG

miR-126 Inhibitor miRisten

Given IV

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER